Interleukin-12 as an adjuvant for cancer immunotherapy

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Interleukin-12 (IL-12) is a cytokine whose main effect is to drive Th-cell differentiation throughout a T helper type 1 cell type of response, thus inducing interferon γ (IFNγ) and favoring a switch from Ig to IgG2a. These properties make IL-12 a candidate adjuvant for vaccination against cancer and infection disease. Enthusiasm was generated in many animal studies where IL-12 was given either systemically or locally. The experience of some toxicity in humans has hampered its further development into clinical applications, which, however, are still possible if restricted to local administration. Gene transfer seems to be the preferred approach to obtain this local release of cytokine. Here we review the applications of IL-12 as adjuvant.

Original languageEnglish
Pages (from-to)114-120
Number of pages7
JournalMethods in Enzymology
Volume19
Issue number1
DOIs
Publication statusPublished - Sep 1999

Fingerprint

Interleukin-12
Immunotherapy
Neoplasms
Cytokines
Gene transfer
Th1 Cells
Interferons
Toxicity
Cell Differentiation
Vaccination
Animals
Switches
Infection
Genes

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Interleukin-12 as an adjuvant for cancer immunotherapy. / Rodolfo, Monica; Colombo, Mario P.

In: Methods in Enzymology, Vol. 19, No. 1, 09.1999, p. 114-120.

Research output: Contribution to journalArticle

@article{b0ef9309e02c444385ca08b704b5d1f1,
title = "Interleukin-12 as an adjuvant for cancer immunotherapy",
abstract = "Interleukin-12 (IL-12) is a cytokine whose main effect is to drive Th-cell differentiation throughout a T helper type 1 cell type of response, thus inducing interferon γ (IFNγ) and favoring a switch from Ig to IgG2a. These properties make IL-12 a candidate adjuvant for vaccination against cancer and infection disease. Enthusiasm was generated in many animal studies where IL-12 was given either systemically or locally. The experience of some toxicity in humans has hampered its further development into clinical applications, which, however, are still possible if restricted to local administration. Gene transfer seems to be the preferred approach to obtain this local release of cytokine. Here we review the applications of IL-12 as adjuvant.",
author = "Monica Rodolfo and Colombo, {Mario P.}",
year = "1999",
month = "9",
doi = "10.1006/meth.1999.0836",
language = "English",
volume = "19",
pages = "114--120",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Interleukin-12 as an adjuvant for cancer immunotherapy

AU - Rodolfo, Monica

AU - Colombo, Mario P.

PY - 1999/9

Y1 - 1999/9

N2 - Interleukin-12 (IL-12) is a cytokine whose main effect is to drive Th-cell differentiation throughout a T helper type 1 cell type of response, thus inducing interferon γ (IFNγ) and favoring a switch from Ig to IgG2a. These properties make IL-12 a candidate adjuvant for vaccination against cancer and infection disease. Enthusiasm was generated in many animal studies where IL-12 was given either systemically or locally. The experience of some toxicity in humans has hampered its further development into clinical applications, which, however, are still possible if restricted to local administration. Gene transfer seems to be the preferred approach to obtain this local release of cytokine. Here we review the applications of IL-12 as adjuvant.

AB - Interleukin-12 (IL-12) is a cytokine whose main effect is to drive Th-cell differentiation throughout a T helper type 1 cell type of response, thus inducing interferon γ (IFNγ) and favoring a switch from Ig to IgG2a. These properties make IL-12 a candidate adjuvant for vaccination against cancer and infection disease. Enthusiasm was generated in many animal studies where IL-12 was given either systemically or locally. The experience of some toxicity in humans has hampered its further development into clinical applications, which, however, are still possible if restricted to local administration. Gene transfer seems to be the preferred approach to obtain this local release of cytokine. Here we review the applications of IL-12 as adjuvant.

UR - http://www.scopus.com/inward/record.url?scp=0032748338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032748338&partnerID=8YFLogxK

U2 - 10.1006/meth.1999.0836

DO - 10.1006/meth.1999.0836

M3 - Article

VL - 19

SP - 114

EP - 120

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - 1

ER -